Topical management of ocular and periocular conditions
AssigneeChronoRX LLC, an Alaska Limited Liability Company
InventorsKenneth Richardson, Don Pearson
Life of this patent
Estimating the term…
Abstract
Chronic glaucoma, cataract, ocular and periocular aging are treated and prevented by the administration of agents that affect metabolic subsystems such as (i) mitochondrial bioenergetics, (ii) free radical moderation and glutathione maintenance, (iii) constitutive nitric oxide/endothelin-1 balance, and (iv) calcium wave signaling and associated neuronal excito-toxicity. Included among the agents are tetrahydrobiopterin, R-alpha-lipoic acid, coenzyme Q10, 17 alpha-estradiol, and glutathione.
Claims44
A method for treating a patient for the prevention, management and clinical amelioration of chronic glaucoma, ocular aging, periocular aging and conditions giving rise thereto, said method comprising administering to said patient a unit dosage form comprising as an active ingredient a therapeutically effective amount of tetrahydrobiopterin.
A method for treating a patient for the prevention, management and clinical amelioration of chronic glaucoma, ocular aging, periocular aging and conditions giving rise thereto, said method comprising administering to said patient a unit dosage form comprising as an active ingredient a therapeutically effective amount of R-alpha-lipoic acid.
A method for treating a patient for the prevention, management and clinical amelioration of chronic glaucoma, ocular aging, periocular aging and conditions giving rise thereto, said method comprising administering to said patient a unit dosage form comprising as an active ingredient a therapeutically effective amount of coenzyme Q10.
A method for treating a patient for the prevention, management and clinical amelioration of chronic glaucoma, ocular aging, periocular aging and conditions giving rise thereto, said method comprising administering to said patient a unit dosage form comprising as an active ingredient a therapeutically effective amount of 17 alpha-estradiol.
A method for treating a patient for the prevention, management and clinical amelioration of chronic glaucoma, ocular aging, periocular aging and conditions giving rise thereto, said method comprising administering to said patient a unit dosage form comprising as an active ingredient a therapeutically effective amount of glutathione.
A unit dosage form for the treatment of ocular and periocular disease in which said unit dosage is in the form of an eyedrop, comprising a therapeutically effective amount of tetrahydrobiopterin from about 0.026% to about 4.00% by weight of said dosage form.
A unit dosage form for the treatment of ocular and periocular disease in which said unit dosage is in the form of an eyedrop, comprising a therapeutically effective amount of R-alpha-lipoic acid from about 0.002% to about 3.15% by weight of said dosage form.
A unit dosage form for the treatment of ocular and periocular disease in which said unit dosage is in the form of an eyedrop, comprising a therapeutically effective amount of coenzyme Q10 from about 0.003% to about 2.250% by weight of said dosage form.
A unit dosage form for the treatment of ocular and periocular disease in which said unit dosage is in the form of an eyedrop, comprising a therapeutically effective amount of 17 alpha-estradiol from about 0.008% to about 2.69% by weight of said dosage form.
A unit dosage form for the treatment of ocular and periocular disease in which said unit dosage is in the form of an eyedrop, comprising a therapeutically effective amount of glutathione from about 0.003% to about 2.383% by weight of said dosage form.
Dependencies are inferred from the claim text.